Related Experiment Video
Updated: Aug 2, 2026
08:27
Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat
Published on: October 29, 2014
Clinical experience with Escherichia coli rHuGM-CSF
International Review of Experimental Pathology
|January 1, 1993
Summary
Recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) reduces infections and intensive care days, improving chemotherapy adherence. Recommended doses are well-tolerated and beneficial for myeloid disorders and post-transplant care.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Myelodysplastic syndromes (MDS) and aplastic anemia (AA) are associated with increased infection risk.
- Bone marrow transplantation (BMT) can lead to prolonged intensive care unit (ICU) stays.
- Cancer chemotherapy and certain viral infections (e.g., AIDS, cytomegalovirus retinitis) can cause myeloid hypoplasia.
Purpose of the Study:
- To evaluate the clinical benefits of recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF).
- To assess the safety and efficacy of rHuGM-CSF in patients with myelodysplastic syndromes, aplastic anemia, post-bone marrow transplant, and viral infections.
- To determine optimal dosing to maximize therapeutic effects while minimizing adverse reactions.
Main Methods:
- Clinical use of rHuGM-CSF in patients with various hematologic and oncologic conditions.
- Monitoring of infection rates, intensive care unit (ICU) days, chemotherapy adherence, and antiviral drug efficacy.
- Dose-ranging studies to identify effective and safe dosage levels.
Main Results:
- rHuGM-CSF significantly reduced infections in patients with MDS and AA.
- Reduced ICU days were observed in allogeneic bone marrow transplant (ABM transplant) recipients.
- Improved adherence to chemotherapy protocols and enhanced efficacy of antiviral therapies were noted.
Conclusions:
- rHuGM-CSF is a valuable adjunctive therapy for managing dysmyelopoiesis and myeloid hypoplasia.
- Recommended doses of rHuGM-CSF are well-tolerated and demonstrate significant patient benefit.
- High doses of rHuGM-CSF should be avoided due to increased adverse reactions and a plateau in biological response.
More Related Videos
Related Concept Videos
01:18Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...
01:18Viral Meningitis
Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...